In this on-demand webinar, Dr. Yvette Stallwood, Head of Early Development Services, shares real-world examples of how early development challenges can impact biologics programs and the strategies used to address them before they affect timelines. Discover how proactive de-risking can help identify manufacturability, expression, product quality, and immunogenicity concerns early, supporting more informed decisions and smoother progression toward the clinic.

Spot risks early

Identify manufacturability, product quality, and immunogenicity challenges before they impact timelines, cost, or program success.

Learn from real case studies

Explore real development challenges, the strategies used to address them, and the outcomes achieved.

Decide with confidence

See how generating the right data early supports stronger candidate selection, informed decision-making, and IND readiness.

You may also be interested in:
Mammalian
Early De-risking & Optimization
Immunogenicity Assessment
Author(s):
Yvette Stallwood, Ph.D.
Head of Early Development Services
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
Webinar (on-demand)
Before IND, Know: How to Overcome Early Development Challenges Before They Impact Your Program
In this on-demand webinar, Dr. Yvette Stallwood, Head of Early Development Services, shares...
CDMO Notes Blog post
How Early Immunogenicity Insights Can Change Bispecific Candidate Selection
When selecting a bispecific candidate, strong potency or binding data may not tell the whole story....
CDMO Notes Blog post
Scaling with Confidence: Why Resilient Upstream Operations Matter for Tech Transfer Success
From engineering runs to GMP execution, learn how manufacturing teams help transform technology...
Poster
GS Ori-Go®: Next-generation CHO expression vectors for enhanced productivity, stability and speed
Lonza is advancing its leading GS Gene Expression System® with the next-generation GS Ori-Go® vector...
Article
Manufacturability and Developability Assessment as the Technical Foundation of a Strong Biologic...
In this article, our expert Michael Hodskinson, Ph.D., discusses why manufacturability and...
Article
Early Protein Expression Assessment and the Value of Starting in a Proven System
In this article our experts discuss the role of early protein expression assessment as a critical...
White paper
Overcoming the Obstacles of Spray-Dried Dispersion Scale-Up
As poorly soluble small-molecule drug candidates continue to challenge development timelines, the...
Article
Early-Stage Biotech Success Starts with the Right Development and Manufacturing Partner
Article
The Specifics of Speed: How to Reach the Clinic Faster While Maintaining Precision
How can mAb programs reach the clinic in as little as six months without increasing CMC risk? Are...
Webinar (on-demand)
Transitioning to AAV Producer Cell Lines: Navigating Comparability, Bridging Studies, and Regulatory...
As AAV-based gene therapies continue to advance toward broader indications, manufacturing...
Article
From Discovery to Delivery: Why Collaboration Is Essential to Advancing Tomorrow's Therapies
The pace of innovation in biotechnology has never been greater. Advances in areas such as precision...
Technical/Service brief
Lonza Early Development Services Brochure
Developing a biologic candidate for clinical studies requires early identification of potential...